VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,878,859 | -1.6% | 409,550 | -3.7% | 0.00% | 0.0% |
| Q2 2023 | $21,228,995 | +232.0% | 425,090 | +149.1% | 0.00% | +100.0% |
| Q1 2023 | $6,394,949 | -20.7% | 170,623 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $8,061,114 | +689.5% | 168,115 | +295.3% | 0.00% | – |
| Q3 2022 | $1,021,000 | -65.9% | 42,533 | -69.1% | 0.00% | – |
| Q2 2022 | $2,996,000 | +39.5% | 137,671 | +54.8% | 0.00% | – |
| Q1 2022 | $2,148,000 | +56.1% | 88,931 | +53.7% | 0.00% | – |
| Q4 2021 | $1,376,000 | +42.4% | 57,843 | +51.9% | 0.00% | – |
| Q3 2021 | $966,000 | +115.1% | 38,076 | +91.6% | 0.00% | – |
| Q2 2021 | $449,000 | +140.1% | 19,876 | +109.9% | 0.00% | – |
| Q1 2021 | $187,000 | -48.1% | 9,471 | -30.1% | 0.00% | – |
| Q4 2020 | $360,000 | +146.6% | 13,559 | +358.2% | 0.00% | – |
| Q3 2020 | $146,000 | +4766.7% | 2,959 | +2859.0% | 0.00% | – |
| Q2 2020 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |